- Home
- LXEH vs RLMD Comparison
LXEH vs RLMD Comparison
Compare LXEH & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEH
- RLMD
- Stock Information
- Founded
- LXEH 2001
- RLMD 2004
- Country
- LXEH China
- RLMD United States
- Employees
- LXEH N/A
- RLMD N/A
- Industry
- LXEH Other Consumer Services
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- LXEH Real Estate
- RLMD Health Care
- Exchange
- LXEH Nasdaq
- RLMD Nasdaq
- Market Cap
- LXEH 25.1M
- RLMD 22.0M
- IPO Year
- LXEH 2020
- RLMD N/A
- Fundamental
- Price
- LXEH N/A
- RLMD $0.63
- Analyst Decision
- LXEH
- RLMD Buy
- Analyst Count
- LXEH 0
- RLMD 3
- Target Price
- LXEH N/A
- RLMD $5.00
- AVG Volume (30 Days)
- LXEH 303.4K
- RLMD 432.4K
- Earning Date
- LXEH 04-30-2025
- RLMD 08-06-2025
- Dividend Yield
- LXEH N/A
- RLMD N/A
- EPS Growth
- LXEH N/A
- RLMD N/A
- EPS
- LXEH N/A
- RLMD N/A
- Revenue
- LXEH $4,493,795.00
- RLMD N/A
- Revenue This Year
- LXEH N/A
- RLMD N/A
- Revenue Next Year
- LXEH N/A
- RLMD N/A
- P/E Ratio
- LXEH N/A
- RLMD N/A
- Revenue Growth
- LXEH N/A
- RLMD N/A
- 52 Week Low
- LXEH $1.20
- RLMD $0.24
- 52 Week High
- LXEH $50.08
- RLMD $4.47
- Technical
- Relative Strength Index (RSI)
- LXEH 29.05
- RLMD 51.09
- Support Level
- LXEH $1.49
- RLMD $0.59
- Resistance Level
- LXEH $1.85
- RLMD $0.67
- Average True Range (ATR)
- LXEH 0.17
- RLMD 0.07
- MACD
- LXEH 0.08
- RLMD -0.02
- Stochastic Oscillator
- LXEH 3.19
- RLMD 52.97
About LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.